No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFIRI Sensitive: A1 - Approval
|
FOLFIRI Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
irinotecan Sensitive: A1 - Approval
|
irinotecan Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFIRINOX Sensitive: A2 - Guideline
|
FOLFIRINOX Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
trifluridine/tipiracil Sensitive: A2 - Guideline
|
trifluridine / tipiracil Sensitive: A2 - Guideline
|
HER-2 amplification
|
Rectal Cancer
|
HER-2 amplification
|
Rectal Cancer
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
HER-2 amplification
|
Rectal Cancer
|
HER-2 amplification
|
Rectal Cancer
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
HER-2 amplification
|
Rectal Cancer
|
HER-2 amplification
|
Rectal Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Rectal Cancer
|
NTRK3 fusion
|
Rectal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Rectal Cancer
|
NTRK2 fusion
|
Rectal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Rectal Cancer
|
NTRK1 fusion
|
Rectal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Rectal Cancer
|
NTRK1 fusion
|
Rectal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Rectal Cancer
|
NTRK2 fusion
|
Rectal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Rectal Cancer
|
NTRK3 fusion
|
Rectal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
BRAF V600
|
Rectal Cancer
|
BRAF V600
|
Rectal Cancer
|
cetuximab + encorafenib Sensitive: A2 - Guideline
|
cetuximab + encorafenib Sensitive: A2 - Guideline
|
BRAF V600
|
Rectal Cancer
|
BRAF V600
|
Rectal Cancer
|
panitumumab + encorafenib Sensitive: A2 - Guideline
|
panitumumab + encorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
ramucirumab Sensitive: A2 - Guideline
|
ramucirumab Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
ziv-aflibercept IV Sensitive: A2 - Guideline
|
ziv-aflibercept IV Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline
|
5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
mFOLFOX6 Sensitive: A2 - Guideline
|
mFOLFOX6 Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
regorafenib Sensitive: A2 - Guideline
|
regorafenib Sensitive: A2 - Guideline
|
UGT1A1*1*1
|
Rectal Cancer
|
UGT1A1*1*1
|
Rectal Cancer
|
capecitabine + irinotecan Sensitive: B - Late Trials
|
capecitabine + irinotecan Sensitive: B - Late Trials
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFIRINOX + mFOLFOX6 Sensitive: B - Late Trials
|
FOLFIRINOX + mFOLFOX6 Sensitive: B - Late Trials
|
PD-L1 expression
|
Rectal Cancer
|
PD-L1 expression
|
Rectal Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
BRAF mutation
|
Rectal Cancer
|
BRAF mutation
|
Rectal Cancer
|
bevacizumab Sensitive: C2 – Inclusion Criteria
|
bevacizumab Sensitive: C2 – Inclusion Criteria
|
TMB-H
|
Rectal Cancer
|
TMB-H
|
Rectal Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
TACC3 expression
|
Rectal Cancer
|
TACC3 expression
|
Rectal Cancer
|
5-fluorouracil Resistant: C3 – Early Trials
|
5-fluorouracil Resistant: C3 – Early Trials
|
TACC3 expression
|
Rectal Cancer
|
TACC3 expression
|
Rectal Cancer
|
FOLFOX Resistant: C3 – Early Trials
|
FOLFOX Resistant: C3 – Early Trials
|
TACC3 expression
|
Rectal Cancer
|
TACC3 expression
|
Rectal Cancer
|
CAPOX Resistant: C3 – Early Trials
|
CAPOX Resistant: C3 – Early Trials
|
TACC3 expression
|
Rectal Cancer
|
TACC3 expression
|
Rectal Cancer
|
capecitabine Resistant: C3 – Early Trials
|
capecitabine Resistant: C3 – Early Trials
|
AFP elevation
|
Rectal Cancer
|
AFP elevation
|
Rectal Cancer
|
mFOLFOX6 Sensitive: C3 – Early Trials
|
mFOLFOX6 Sensitive: C3 – Early Trials
|
EZH2 underexpression
|
Rectal Cancer
|
EZH2 underexpression
|
Rectal Cancer
|
capecitabine Sensitive: C3 – Early Trials
|
capecitabine Sensitive: C3 – Early Trials
|
RUNX3 overexpression
|
Rectal Cancer
|
RUNX3 overexpression
|
Rectal Cancer
|
capecitabine Sensitive: C3 – Early Trials
|
capecitabine Sensitive: C3 – Early Trials
|
KRAS mutation
|
Rectal Cancer
|
KRAS mutation
|
Rectal Cancer
|
SOXIRI Sensitive: C3 – Early Trials
|
SOXIRI Sensitive: C3 – Early Trials
|
NRAS mutation
|
Rectal Cancer
|
NRAS mutation
|
Rectal Cancer
|
SOXIRI Sensitive: C3 – Early Trials
|
SOXIRI Sensitive: C3 – Early Trials
|
HRAS mutation
|
Rectal Cancer
|
HRAS mutation
|
Rectal Cancer
|
SOXIRI Sensitive: C3 – Early Trials
|
SOXIRI Sensitive: C3 – Early Trials
|
NRAS mutation
|
Rectal Cancer
|
NRAS mutation
|
Rectal Cancer
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
HRAS mutation
|
Rectal Cancer
|
HRAS mutation
|
Rectal Cancer
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
KRAS mutation
|
Rectal Cancer
|
KRAS mutation
|
Rectal Cancer
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
KRAS mutation + ATM mutation
|
Rectal Cancer
|
KRAS mutation + ATM mutation
|
Rectal Cancer
|
bevacizumab Sensitive: C4 – Case Studies
|
bevacizumab Sensitive: C4 – Case Studies
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
ipilimumab Sensitive: C4 – Case Studies
|
ipilimumab Sensitive: C4 – Case Studies
|
RAS wild-type + BRAF wild-type
|
Rectal Cancer
|
RAS wild-type + BRAF wild-type
|
Rectal Cancer
|
panitumumab Sensitive: C4 – Case Studies
|
panitumumab Sensitive: C4 – Case Studies
|
PAI1 expression
|
Rectal Cancer
|
PAI1 expression
|
Rectal Cancer
|
AZD1208 Sensitive: D – Preclinical
|
AZD1208 Sensitive: D – Preclinical
|